ClinicalTrials.Veeva

Menu

The DANCEREX Proof-of-Concept Study for Chronic Neurological Disorders (DANCEREX-DTx)

D

Don Carlo Gnocchi Onlus Foundation

Status

Enrolling

Conditions

Neurocognitive Impairment, Mild
Sclerosis, Multiple
Neurocognitive Dysfunction

Treatments

Device: Educational Program
Device: Multidimensional dance-based program
Device: DANCEREX-DTx

Study type

Interventional

Funder types

Other

Identifiers

NCT06112639
DANCEREX-DTx

Details and patient eligibility

About

The goal of this clinical trial is to test a new digital therapeutic solution which combines a holistic, multidimensional rehabilitation program based on dance and music with an innovative motivational system (DANCEREX-DTx) in Chronic Neurological Disorders (Multiple Sclerosis and pre-Mild Cognitive Impairment - MCI/ MCI at risk of Alzheimer's Disease). The main questions it aims to answer are 1] efficacy of the digital therapeutic solution in terms of adherence, clinical/functional measures, quality of life and surrogate measures; 2] usability and acceptability of the system.

Participants will be randomized (with an allocation ratio of 2:2:1) into the experimental group (DANCEREX - 24 sessions of multidimensional dance-based program integrated with an innovative motivational system), active comparator group (24 sessions of multidimensional dance-based program) and placebo group (24 sessions of educational program). Researchers will compare the experimental group to the other two groups to see if a digital therapeutic solution integrating a multidimensional dance-based program and motivational system is effective in increasing adherence to rehabilitation treatment.

Enrollment

192 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. age between 18 and 85 years (adult and older adult);
  2. education equal to or more than five years
  3. agreement to participate with the signature of the informed consent form;
  4. clinical diagnosis of Multiple Sclerosis (MS) according to the 2017 revised criteria of MC Donald - Expanded Disability Status Scale (EDSS) score equal or less than 4.5, R-R disease course, freedom from relapses, and steroid treatment for at least one month, OR clinical diagnosis of pre-Mild Cognitive Impairment - MCI (Subjective Memory Complaints and/or Subjective Cognitive Complaints)/MCI at risk of Alzheimer's Disease with the Clinical Dementia Rating (CDR) scale equal or less than 0.5
  5. Normal score to a screening test for cognitive impairment (Montreal Cognitive Assessment test - MoCA test > 15.5 Santangelo et al., 2015)

Exclusion criteria

  1. presence of comorbidities that prevent patients from undertaking a safe home program (e.g., balance problems, history of falls in the past 6 months, use of assistive devices for deambulation)
  2. presence of overt hearing/visual impairment
  3. for the MCI group, the absence of a caregiver/study partner able to support the participant;
  4. no living in one's own home;
  5. for the MS group, score in cerebellum function at EDSS greater than 3

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

192 participants in 3 patient groups, including a placebo group

DANCEREX Treatment
Experimental group
Description:
Multidimensional dance-based program with motivational support integrated into applied game. The treatment will last 12 weeks with a frequency of two sessions a week, each lasting about 45 min.
Treatment:
Device: DANCEREX-DTx
Multidimensional dance-based program
Active Comparator group
Description:
Multidimensional dance-based program without motivational support. The treatment will last 12 weeks with a frequency of two sessions a week, each lasting about 45 min.
Treatment:
Device: Multidimensional dance-based program
Educational Program
Placebo Comparator group
Description:
Educational/informative videos on managing of clinical conditions.The program will last 12 weeks with a frequency of two sessions a week, each lasting about 45 min.
Treatment:
Device: Educational Program

Trial contacts and locations

3

Loading...

Central trial contact

Francesca Borgnis, PhD; Francesca Baglio, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems